简体
简体中文
繁體中文

FTI咨询 FCN

已收盘 08-07 16:00:00 美东时间

151.43

+0.560

+0.37%

华盛通华盛通
立即下载
  • 最 高154.24
  • 今 开149.99
  • 成交量 44.39万股
  • 最 低 149.52
  • 昨 收 150.87
  • 总市值 41.81亿
  • 52周最高 189.30
  • 市盈率 18.38
  • 换手率 1.61%
  • 52周最低 137.65
  • 委 比 72.41%
  • 总股本 2761.16万
  • 历史最高 243.60
  • 量 比 0.88
  • 振 幅 3.13%
  • 历史最低 22.88
  • 每 手 1
  • 风险率 9.53%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • 财报速睇 | FTI咨询 2026财年Q2营收9.93亿美元,同比增长5.3%;归母净利润0.58亿美元,同比下滑19.4%

    华盛资讯8月1日讯,FTI咨询公布2026财年Q2业绩,公司Q2营收9.93亿美元,同比增长5.3%,归母净利润0.58亿美元,同比下滑19.4%。

    08-01 04:47

  • FTI Consulting Lowers FY2026 GAAP EPS Guidance from $8.90-$9.60 to $8.70-$9.30 vs $9.14 Est

    FTI Consulting (NYSE:FCN) lowers FY2026 GAAP EPS guidance from $8.90-$9.60 to $8.70-$9.30 vs $9.14 analyst estimate..

    07-30 19:33

  • EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

    EyePoint, Inc. announced the completion of enrollment for its COMO and CAPRI Phase 3 clinical trials for DURAVYU™, a treatment for diabetic macular edema (DME). Over 480 participants were enrolled in five months, ahead of schedule. Topline data from both trials is expected in the fourth quarter of 2027. DURAVYU™ aims to provide a more durable and differentiated treatment option with a sustained drug delivery system targeting both VEGF and inflamm...

    07-30 11:00

  • Notice of Results

    Diversified Energy Company (NYSE: DEC, LSE: DEC) has announced that it will release its second quarter 2026 operational and financial results on August 5, 2026, after U.S. market close. A conference call to discuss the results will be held on August 6, 2026, at 8:30 AM EST (1:30 PM GMT). The results and supplementary presentation will be available on the company's website at https://ir.div.energy/financial-info and https://ir.div.energy/presentat...

    07-29 22:22

  • Marex Group Limited to announce second quarter 2026 results on August 12, 2026

    Marex Group Limited announced it will release its fiscal 2026 second quarter results before market open on August 12, 2026. The earnings release and supplementary materials will be available on the Marex website. A conference call to discuss the results will take place at 9am ET the same day. Marex provides market access, infrastructure services, and liquidity to clients across global commodity and financial markets, with a presence in major meta...

    07-27 11:00

  • GoHealth Successfully Completes Financial Restructuring and Emerges Well Positioned for Future Success

    GoHealth has successfully completed its financial restructuring under Chapter 11 and emerged with a stronger capital structure, positioning itself to continue as a leading Medicare-focused digital health company. With new ownership and improved flexibility, the company aims to maintain its market position and serve its Medicare consumers and partners effectively.

    07-21 20:12

  • EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    EyePoint, Inc. granted non-statutory stock options to two new employees, totaling 63,500 shares, as inducement awards under NASDAQ Listing Rule 5635(c)(4). The options, with an exercise price of $13.85 per share, vest over four years and have a ten-year term. EyePoint, a biopharmaceutical company, is developing DURAVYU™, an investigational treatment for retinal diseases, currently in Phase 3 trials for wet AMD and DME. The company is based in Wat...

    07-16 11:00

  • EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

    EyePoint, Inc. appoints Tarek S. Hassan, M.D., as Senior Vice President and Chief Strategic Science Officer. Dr. Hassan, a globally recognized retina specialist with over 35 years of experience, will provide strategic guidance for the Company’s clinical development and commercialization efforts, particularly for its lead program, DURAVYU™, which is in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. His expertis...

    07-13 11:00